The 5-HT2A serotoninergic receptor is expressed in the MCF-7 human breast cancer cell line and reveals a mitogenic effect of serotonin

Biochemical and Biophysical Research Communications

Volumn 343, Issue 4, 2006, Pages 1053-1059

  Sonier, Brigitte ^a   Arseneault, Madeleine ^a,c   Lavigne, Carole ^a   Ouellette, Rodney J ^b   Vaillancourt, Cathy ^a,c  

^a UNIVERSITÉ DE MONCTON   (Canada)

^b Beausejour Medical Research Institute   (Canada)

^c INRS INSTITUT ARMAND FRAPPIER   (Canada)

Author keywords

5 HT2A receptors; Breast cancer; MCF 7 cells; Proliferation; Serotonin

Indexed keywords

4 IODO 2,5 DIMETHOXYAMPHETAMINE; MESSENGER RNA; RECEPTOR SUBTYPE; SEROTONIN; SEROTONIN 2A AGONIST; SEROTONIN 2A RECEPTOR; 4-IODO-2,5-DIMETHOXYPHENYLISOPROPYLAMINE; AMPHETAMINE DERIVATIVE;

AMINO ACID SEQUENCE; ARTICLE; AUTOMATION; BRAIN CORTEX; BREAST CANCER; CANCER CELL; CANCER GROWTH; CELL MEMBRANE; CELL STIMULATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MITOGENESIS; NITROBLUE TETRAZOLIUM TEST; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROMBOCYTE; WESTERN BLOTTING; BIOSYNTHESIS; BREAST TUMOR; CELL PROLIFERATION; DRUG EFFECT; DRUG POTENTIATION; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALIA; MINK CELL FOCUS-FORMING VIRUS;

AMPHETAMINES; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MEMBRANE; CELL PROLIFERATION; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; RECEPTOR, SEROTONIN, 5-HT2A; RNA, MESSENGER; SEROTONIN;

EID: 33646045331     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.03.080     Document Type: Article

References (34)

1. Lauder J.M., Wallace J.A., and Krebs H. Roles for serotonin in neuroembryogenesis. Adv. Exp. Med. Biol. 133 (1981) 477-506
2. Tutton P.J.M., and Barkla D.H. Biogenic amines as regulators of the proliferative activity of normal and neoplastic intestinal epithelial cells (review). Anticancer Res. 7 (1987) 1-12
3. Fecteau K.A., and Eiler H. Placenta detachment: unexpected high concentrations of 5-hydroxytryptamine (serotonin) in fetal blood and its mitogenic effect on placental cells in bovine. Placenta 22 (2001) 103-110
4. Ishizuka J., Beauchamp D., Townsend Jr. C.M., Greeley Jr. G.H., and Thompson J.C. Receptor-mediated autocrine growth-stimulatory effect of 5-hydroxytryptamine on cultured human pancreatic carcinoid cells. J. Cell. Physiol. 150 (1992) 1-7
5. Cattaneo M.G., Codignola A., Vicentini L.M., Clementi F., and Sher E. Nicotine stimulates a serotoninergic autocrine loop in human small-cell lung carcinoma. Cancer Res. 53 (1993) 5566-5568
6. Sonier B., Lavigne C., Arseneault M., Ouellette R., and Vaillancourt C. Expression of the 5-HT2A serotoninergic receptor in human placenta and choriocarcinoma cells: mitogenic implications of serotonin. Placenta 26 (2005) 484-490
7. Hoyer D., Clarke D.E., Fozard J.R., Hartig P.R., Martin G.R., Mylecharane E.J., Saxena P.R., and Humphrey P.P. International union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol. Rev. 46 (1994) 157-203
8. Raymond J.R., Mukhin Y.V., Gelasco A., Turner J., Collinsworth G., Gettys T.W., Grewal J.S., and Garnovskaya M.N. Multiplicity of mechanisms of serotonin receptor signal transduction. Pharmacol. Ther. 92 (2001) 179-212
9. 2A receptor. Am. J. Physiol. 268 1 Pt 2 (1995) F122-F127
10. 2A receptor coupled to the Jak/STAT pathway. J. Biol. Chem. 272 (1997) 14825-14829
11. Banes A.K.L., Shaw S.M., Tawfik A., Patel B.P., Ogbi S., Fulton D., and Marrero M.B. Activation of the JAK/STAT pathway in vascular smooth muscle by serotonin. Am. J. Physiol. Cell Physiol. 288 (2005) C805-C812
12. 2A receptor induces TGF-β1 expression in mesangial cells via Erk: proliferative and fibrotic signals. Am. J. Physiol. 276 6 Pt 2 (1997) F922-F930
13. Watts S.W., Yang P., Banes A.K., and Baez M. Activation of Erk mitogen-activated protein kinase proteins by vascular serotonin receptors. J. Cardiovasc. Pharmacol. 38 (2001) 539-551
14. Julius D., Huang K.M., Livelli T.J., Axel R., and Jesell T.M. The 5-HT2 receptor defines a family of structurally distinct but functionally conserved serotonin receptors. Proc. Natl. Acad. Sci. USA 87 (1990) 928-932
15. Sharpe C.R., Collet J.-P., Belzile E., Hanley J.A., and Boivin J.-F. The effects of tricyclic antidepressants on breast cancer risk. Br. J. Cancer 86 (2002) 92-97
16. Cotterchio M., Kreiger N., Darlington G., and Steingart A. Antidepressant medication use and breast cancer risk. Am. J. Epidemiol. 151 (2000) 951-957
17. Kelly J.P., Rosenberg L., Palmer J.R., Rao R.S., Strom B.L., Stolley P.D., Zauber A.G., and Shapiro S. Risk of breast cancer according to use of antidepressants, phenothiazines, and antihistamines. Am. J. Epidemiol. 150 (1999) 861-868
18. Wang P.S., Walker A.M., Tsuang M.T., Orav E.J., Levin R., and Avorn J. Antidepressant use and the risk of breast cancer: a non-association. J. Clin. Epidemiol. 54 (2001) 728-734
19. Brandes L.J., Arron R.J., Bogdanovic R.P., Tong J., Zaborniak C.L., Hogg G.R., Warrington R.C., Fang W., and LaBella F.S. Stimulation of malignant growth in rodents by antidepressant drugs at clinically relevant doses. Cancer Res. 52 (1992) 3796-3800
20. Hilakivi-Clark L., Wright A., and Lippman M.E. DMBA-induced mammary tumor growth in rats exhibiting increased or decreased ability to cope with stress due to early postnatal handling or antidepressant treatment. Physiol. Behav. 54 (1993) 229-236
21. Moorman P.G., Grubber J.M., Millikan R.C., and Newman B. Antidepressant medications and their association with invasive breast cancer and carcinoma in situ of the breast. Epidemiology 14 (2003) 307-314
22. Matsuda M., Imaoka T., Vomachka A.J., Gudelsky G.A., Hou Z., Mistry M., Bailey J.P., Nieport K.M., Walther D.J., Bader M., and Horseman N.D. Serotonin regulates mammary gland development via an autocrine-paracrine loop. Dev. Cell 6 (2004) 193-203
23. Bradford M.M. A rapid and sensitive method for the quantition of microgram quantities of protein utilizing the principle of dye-binding. Anal. Biochem. 72 (1976) 248-254
24. 2A receptor. J. Histochem. Cytochem. 46 (1998) 811-824
25. Yuan Q., Harley C.W., and McLean J. Mitral Cell β1 and 5-HT2A receptor colocalization and camp coregulation: a new model of norepinephrine-induced learning in the olfactory bulb. Learn. Mem. 10 (2003) 5-15
26. Blask D.E., and Hill S.M. Effects of melatonin on cancer: studies on MCF-7 human breast cancer cells in culture. J. Neural Transm. Suppl. 21 (1986) 433-449
27. Seuwen K., and Pouysségur J. Serotonin as a growth factor. Biochem. Pharmacol. 39 (1990) 985-990
28. Pezzella G., Moslinger-Gehmayr R., and Contu A. Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptline. Breast Cancer Res. Treat. 70 (2001) 1-10
29. National Cancer Institute of Canada: Canadian Cancer Statistics 2005. Produced by Canadian Cancer Society, National Cancer Institute of Canada, Statistic Canad, Provincial/Territorial Cancer Registries and Public Health Agency of Canada, Toronto, Canada, 2005.
30. Steingart A.B., and Cotterchio M. Do antidepressans cause, promote, or inhibit cancers. J. Clin. Epidemiol. 48 (1995) 1407-1412
31. Stearns V., and Hayes D.F. Approach to menopausal symptoms in women with breast cancer. Curr. Treat. Options Oncol. 3 (2002) 179-190
32. Weitzner M.A., Moncello J., Jacobsen P.B., and Minton S. A pilot trial of paroxetine for the treatment of hot flashes and associated symptoms in women with breast cancer. J. Pain Symptom Manage. 23 (2002) 337-345
33. Brandes L.J., Macdonald L.M., and Bogdanovic R.P. Evidence that the antiestrogen binding site is a histamine or histamine-like receptor. Biochem. Biophys. Res. Commun. 126 (1985) 905-910
34. Brandes L.J., Beecroft W.A., and Hogg G.R. Stimulation of in vivo tumor growth and phorbol ester-induced inflammation by N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethamine HCl, a potent ligand for intracellular histamine receptors. Biochem. Biophys. Res. Commun. 179 (1991) 1297-1304